Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 6/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.41 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17448054 | 0.83 | NR1H4 (0.42) | PTGS2NOTUMNR1H4MALT1SLC16A3 | |
| SCHEMBL22769348 | 0.83 | NR1H4 (0.45) | PTGS2NR1H4CA1CA2CA9 | |
| SCHEMBL21807369 | 0.83 | CSNK1D (0.46) | PTGS2NR1H4CA1CA2CA9 | |
| SCHEMBL1779503 | 0.83 | PTGS2 (0.52) | PTGS2NOTUMNR1H4SLC16A3CNR2 | |
| SCHEMBL20805341 | 0.82 | NR1H4 (0.44) | PTGS2NR1H4CYP1A2CA1CA2 | |
| SCHEMBL19272866 | 0.82 | MARS1 (0.53) | PTGS2NOTUMMALT1SLC16A3SLC16A1 | |
| SCHEMBL10356476 | 0.77 | MAPK1 (0.42) | PTGS2NOTUMMALT1CYP1A2CYP3A4 | |
| SCHEMBL22722186 | 0.77 | NR1H4 (0.40) | PTGS2NR1H4CYP3A4CNR2CA1 | |
| SCHEMBL2424899 | 0.76 | NR1H4 (0.42) | PTGS2NR1H4CA1CA2CA9 | |
| SCHEMBL3491201 | 0.75 | KDM4E (0.50) | PTGS2NOTUMUSP2TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2017140758-A1 | DERIVATIVES OF 2-AMINO-4-(2-OXAZOLIDINON-3-YL)-PYRIMIDINE FUSED WITH A FIVE-MEMBERED HETEROAROMATIC RING IN 5,6-POSITION WHICH ARE USEFUL FOR THE TREATMENT OF VARIOUS CANCERS | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2017-08-24 | — | — | WO | disclosed |
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | PTGS2 436/4885NOTUM 1/4885NR1H4 257/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | PTGS2 632/4885NOTUM 5/4885NR1H4 68/4885 |
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | PTGS2 1571/4885NOTUM 1118/4885NR1H4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.